What ' s the Evidence Base for Prescribing New SSc-ILD Drugs? What ' s the Evidence Base for Prescribing New SSc-ILD Drugs?

Two experts from Hospital for Special Surgery review the evidence for how best to use nintedanib, tocilizumab, and combination therapy in treating patients with systemic sclerosis –associated ILD.Hospital for Special Surgery
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news